TY - JOUR
T1 - The economic consequences of US FDA new drug approvals
T2 - evidence from Taiwan pharmaceutical and biotech companies
AU - Chen, Yong Jie
AU - Feng, Zhi Yuan
AU - Li, Yueh Ping
AU - Huang, Hua Wei
N1 - Funding Information:
We gratefully acknowledge the financial support of the National Science Council, Taiwan, ROC [Project No. NSC 103-2410-H-006 ?026 -MY2].
PY - 2020
Y1 - 2020
N2 - This study examines the association between the new drug approvals released by the US Food and Drug Administration (FDA) and subsequent market stock price reactions for listed pharmaceutical and biotech companies in Taiwan. We find that new drug approvals released by the US FDA lead to significantly positive stock price cumulative abnormal returns (CARs) in most stages of the new drug approval process, in particular, for the phase 3 stage. This implies that public investors are more willing to invest in the later stages of the US FDA approval process due to the high failure rate of drug verification. We also find that research and development (R&D) investment has significantly positive impacts on CARs. Since R&D investments may substantially reduce the taxes and operating costs of pharmaceutical and biotech companies, they are positively related to stock price returns and serve as an important indicator for market investors. Finally, we find that the effect of R&D investment on CARs associated with FDA approvals is more prominent in the period after the passage of the ‘Taiwanese Biotech and New Pharmaceutical Development Act’, indicating that tax incentives or policy effects indeed influence market responses.
AB - This study examines the association between the new drug approvals released by the US Food and Drug Administration (FDA) and subsequent market stock price reactions for listed pharmaceutical and biotech companies in Taiwan. We find that new drug approvals released by the US FDA lead to significantly positive stock price cumulative abnormal returns (CARs) in most stages of the new drug approval process, in particular, for the phase 3 stage. This implies that public investors are more willing to invest in the later stages of the US FDA approval process due to the high failure rate of drug verification. We also find that research and development (R&D) investment has significantly positive impacts on CARs. Since R&D investments may substantially reduce the taxes and operating costs of pharmaceutical and biotech companies, they are positively related to stock price returns and serve as an important indicator for market investors. Finally, we find that the effect of R&D investment on CARs associated with FDA approvals is more prominent in the period after the passage of the ‘Taiwanese Biotech and New Pharmaceutical Development Act’, indicating that tax incentives or policy effects indeed influence market responses.
UR - http://www.scopus.com/inward/record.url?scp=85087643674&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087643674&partnerID=8YFLogxK
U2 - 10.1080/14479338.2020.1786389
DO - 10.1080/14479338.2020.1786389
M3 - Article
AN - SCOPUS:85087643674
SP - 1
EP - 21
JO - Innovation: Management, Policy and Practice
JF - Innovation: Management, Policy and Practice
SN - 1447-9338
ER -